An Open-Label Prospective Observational Study of Tralokinumab in Atopic Dermatitis Patients with Inadequate Response to Dupilumab-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

An Open-Label Prospective Observational Study of Tralokinumab in Atopic Dermatitis Patients with Inadequate Response to Dupilumab

Published:2024-08-01 Issue: Volume: Page:
ISSN:1710-3568
Container-title:Dermatitis®
language:en
Short-container-title:Dermatitis®

Author:

Polaskey Meredith Tyree¹²,Fakhraie Sheiva³,Daftary Karishma³,Chovatiya Raj¹²³^ORCID

Affiliation:

1. Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, IL, USA

2. Center for Medical Dermatology and Immunology Research, Chicago, IL, USA

3. Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, IL, USA

Publisher

Mary Ann Liebert Inc

Link

https://www.liebertpub.com/doi/pdf/10.1089/derm.2024.0084

Reference5 articles.

1. Atopic dermatitis

2. Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis

3. Switching from dupilumab to tralokinumab in patients with atopic dermatitis due to inefficacy or side effects

4. Current treatment goals are achieved by the majority of patients with atopic dermatitis treated with tralokinumab: results from a multicentric, multinational, retrospective, cohort study

5. Tralokinumab shows clinical improvement in patients with prurigo nodularis-like phenotype atopic dermatitis: A multicenter, prospective, open-label case series study

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP